The Journal of Clinical Psychopharmacology Podcast

The Journal of Clinical Psychopharmacology
  • 4.5 (13)
  • MEDICINE
  • UPDATED DAILY

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

  1. 12/19/2025

    Reduction of Loss of Control Eating in Youth With Attention-Deficit/Hyperactivity Disorder Following Initiation of Stimulant Medication: A Prospective Study

    In youth, binge eating is often marked by loss of control eating (LOC-E), defined as difficulty stopping eating and persistent, compulsive food-seeking behaviors that occur even in the absence of physical hunger. In this podcast, Dr. Aaron Keshen discusses his article, titled, "Reduction of Loss of Control Eating in Youth With Attention-Deficit/Hyperactivity Disorder Following Initiation of Stimulant Medication: A Prospective Study." In their article, the authors describe a prospective observational study that aimed to examine changes in LOC-E over a 3-month period in youth with comorbid attention-deficit/hyperactivity disorder and LOC-E who initiated stimulant medication.   The other authors are Colby Price, Elena Koning, Anastasia L. Harris, Nami Trappenberg, Anja Hilbert, Sara Bartel, Jill Chorney, Laura Dixon, Joseph Sadek, Guido K.W. Frank, Victoria Taylor, Wanda Rasmussen, Hanif Chatur, Drew Yamada, and Stuart B. Murray. The article is published in the January-February 2026 issue of The Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002106

    7 min

  2. 12/19/2025

    Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study

    Treatment-resistant depression (TRD) is a considerable clinical challenge. Esketamine, in conjunction with an oral antidepressant, is a potential treatment for TRD. In this podcast, Dr. Matteo Lupi discusses his article, "Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study." The prospective study described in the report explores the long-term effects of esketamine therapy on subjective quality of life in adults with TRD.   The other contributing authors are Alessandro Carano, Tiziano Acciavatti, Stefano Marini, Marco Palmucci, Elicio Marinucci, Enrico Paolini, Alessandro Gentile, Angelomarco Barioglio, Marco Giri, Domenico De Berardis, and Giovanni Martinotti. The article is published in the January-February 2026 issue of The Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002042

    4 min

  3. 12/19/2025

    Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis

    Atomoxetine is a selective norepinephrine reuptake inhibitor prescribed for the management of attention-deficit hyperactivity disorder (ADHD).  In this podcast, Emily Yamada discusses her article "Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis." In their article, Yamada and her colleagues present data showing that there is minimal transfer of atomoxetine in breast milk, suggesting that maternal atomoxetine use poses a very low risk to breastfed infants, making it a suitable choice for medication management of ADHD in lactating women. The other contributing authors are Shraddha Trehan, Amy Stark, Kaytlin Krutsch, and Palika Datta. The article is published in the January-February 2026 issue of The Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002109

    8 min

  4. 11/03/2025

    Diet Drug Interactions: Achieving and Maintaining Ketosis As Adjunct to Psychotropic Polypharmacotherapy

    As interest grows in the therapeutic potential of ketogenic diets for bipolar disorder, careful attention must be given to drug-diet interactions. Overlapping mechanisms between therapeutic ketosis and mood-stabilizing agents may offer opportunities for synergistic effects, but may also introduce risks related to altered pharmacokinetics, pharmacodynamics, and additive toxicities. In this podcast, Dina N. Ali, MD, and Jonathan Leung, PharmD, discuss the complex picture of trying to optimize treatment outcomes while many research questions are yet to be answered. Ali and Leung are authors of the commentary, "Diet Drug Interactions: Achieving and Maintaining Ketosis As Adjunct to Psychotropic Polypharmacotherapy," which is published in the November-December 2025 issue of the Journal of Clinical Psychopharmacology. The other contributing authors are Mark A. Frye, MD; Iain H. Campbell, PhD; Matej Markota, MD; Mikaela M. Hofer, PharmD, and Heather Standorf, PharmD. doi: 10.1097/JCP.0000000000002074

    11 min

  5. 11/03/2025

    Anticholinergic Equivalence in Psychotropic Medications: A Guide for Psychiatrists

    In this podcast, Nicolas Badre, MD, and Eric Geier, MD, PhD, discuss their article, "Anticholinergic Equivalence in Psychotropic Medications: A Guide for Psychiatrists," which is published in the November-December 2025 issue of the Journal of Clinical Psychopharmacology. Anticholinergic side effects from psychotropic medications are common and can lead to significant adverse events, including cognitive impairment and falls, particularly in vulnerable populations like the elderly. The cumulative anticholinergic burden from multiple medications is a critical concern associated with poorer clinical outcomes. Quantifying this burden is essential for safer prescribing. For their article, they developed a table to provide a practical tool for psychiatrists to quantify and compare the anticholinergic potential of psychotropic medications. doi: 10.1097/JCP.0000000000002073

    16 min

  6. 08/27/2025

    Fact Versus Fear: Antidepressants in Children and Adolescents

    A presidential executive order early this year directed federal departments and agencies to address the issue of chronic disease in the United States, including "the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors (SSRIs)," with a particular focus on youth. In this podcast, Dr. Jeffrey R. Strawn discusses his editorial, "Fact Versus Fear: Antidepressants in Children and Adolescents," which is published in the September-October 2025 issue of the Journal of Clinical Psychopharmacology. In the editorial, Dr. Strawn and his coauthor, Dr. John T. Walkup, write that the framing of the issue in the executive order risks reinforcing stigma and diminishing trust in evidence-based pediatric mental health care. The editorial summarizes the evidence supporting the efficacy, safety, and tolerability of SSRIs in youth and contextualizes these findings within a discussion of the risk of withholding potentially effective treatments due to stigma and misinformation. The editorial is published in the September-October 2025 issue of the Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002054

    8 min

  7. 08/27/2025

    How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression?

    Many patients view the return of "positive mental health" (PMH) to be their most important goal of treatment for major depressive disorder (MDD). However, few studies have systematically measured PMH or prospectively examined the added value of considering PMH as a treatment predictor of outcomes. In this podcast, Dr. Somaia Mohamed discusses her article, "How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report." Dr. Mohamed and her coauthors found that high PMH scores at baseline were associated with a greater chance of remission. The article is published in the September-October 2025 issue of the Journal of Clinical Psychopharmacology. In addition to Dr. Mohamed, the other authors are Sidney Zisook, Gary R. Johnson, and Beata Planeta. doi: 10.1097/JCP.0000000000002051

    9 min

  8. 08/27/2025

    Variability in Response to Antidepressants

    Antidepressants are in widespread use, but there is considerable variability in how patients respond, with some seeing substantial improvement while others respond only partially or not at all. In this podcast, Dr. Antonio E. Nardi discusses the many factors that underlie response rates, including psychological factors, personality traits, and medication adherence. There are also some mood conditions such as demoralization that may seem to resemble depression but do not meet all the clinical criteria. Recognizing these different emotional states is crucial for both individuals and clinicians in the treatment of low mood disorders. Dr. Nardi, along with Drs. Richard I. Shader, Richard Balon, Anthony J. Rothschild, and Larissa Junkes, are the authors of an editorial titled, " 'I am depressed': The many meanings that may underlie variability in response to antidepressants." The editorial is published in the September-October 2025 issue of the Journal of Clinical Psychopharmacology. doi: 10.1097/JCP.0000000000002053

    9 min
See All (66)

Ratings & Reviews

4.5
out of 5
13 Ratings

About

A podcast detailing current topics in the Journal of Clinical Psychopharmacology.

Information

You Might Also Like